David Hutchful

David Hutchful

Auto-generated profile, based on publicly available information

David Hutchful

Yemaachi Biotech Ltd

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2019 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MWMichelle Willcox
Michelle Willcox
AMAnitha Moorthy
Anitha Moorthy
DMDiwakar Mohan
Diwakar Mohan
KRKaren Romano
Karen Romano
DHDavid Hutchful
David Hutchful
ALAmnesty LeFevre
Amnesty LeFevre
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Mobile technologies are emerging as tools to enhance health service delivery systems and empower clients to improve maternal, newborn and child health. Limited evidence exists on the value for money of mobile health programs in low and middle income countries. Objective: This study aims to forecast the incremental cost effectiveness of the Mobile Technology for Community Health (MOTECH) initiative at scale across 170 districts in Ghana. Methods: MOTECH’s “Client Data Application" allows frontline health workers to digitize service delivery information and track care for patients. MOTECH’s other main component, the “Mobile Midwife”, sends automated educational voice messages to mobile phones of pregnant and postpartum women. We measured program costs and consequences of scaling up MOTECH over a 10-year analytic time horizon. Economic costs were estimated from informant interviews and financial records. Health effects were modeled using the Lives Saved Tool with data from an independent evaluation of changes in key services coverage observed in Gomoa West. Incremental cost effectiveness ratios are presented overall and for each year of implementation. Uncertainty analyses assessed the robustness of results to changes in key parameters. Results: MOTECH was scaled in clusters over a 3-year period to reach 170 (78%) of Ghana’s 216 districts. Sustaining the program would cost $17,618 on average annually per district. Over 10-years, MOTECH could potentially save an estimated 59,906 lives at total cost of $32 million. The incremental cost per DALY averted ranged from $174 in year 1 to $6.54 in the 10th year of implementation, and $20.94 (95% CI: $20.34-$21.55) over 10 years. Uncertainty analyses suggest that the ICER is most sensitive to changes in health effects, followed by personnel time. Probabilistic sensitivity analyses suggest that MOTECH has a 100% probability of being cost effective above a willingness to pay threshold of USD $50. Conclusions: This is the first study to estimate the value for money of a supply- and demand-side mobile health initiative. The adoption of MOTECH to improve MNCH service delivery and uptake represents good value for money in Ghana and should be considered for expansion. Integration with other mobile health solutions, including eTracker, may provide opportunities to continue or combine beneficial components of MOTECH to achieve greater impact for health. Clinical Trial: Not applicable

10 June 2018 in JMIR Preprints
Verified
Preprint
Open access
MWMichelle Willcox
Michelle Willcox
AMAnitha Moorthy
Anitha Moorthy
DMDiwakar Mohan
Diwakar Mohan
KRKaren Romano
Karen Romano
DHDavid Hutchful
David Hutchful
ALAmnesty LeFevre
Amnesty LeFevre
BACKGROUND Mobile technologies are emerging as tools to enhance health service delivery systems and empower clients to improve maternal, newborn, and child health. Limited evidence exists on the value for money of mobile health (mHealth) programs in low- and middle-income countries. OBJECTIVE This study aims to forecast the incremental cost-effectiveness of the Mobile Technology for Community Health (MOTECH) initiative at scale across 170 districts in Ghana. METHODS MOTECH’s “Client Data Application” allows frontline health workers to digitize service delivery information and track the care of patients. MOTECH’s other main component, the “Mobile Midwife,” sends automated educational voice messages to mobile phones of pregnant and postpartum women. We measured program costs and consequences of scaling up MOTECH over a 10-year analytic time horizon. Economic costs were estimated from informant interviews and financial records. Health effects were modeled using the Lives Saved Tool with data from an independent evaluation of changes in key services coverage observed in Gomoa West District. Incremental cost-effectiveness ratios were presented overall and for each year of implementation. Uncertainty analyses assessed the robustness of results to changes in key parameters. RESULTS MOTECH was scaled in clusters over a 3-year period to reach 78.7% (170/216) of Ghana’s districts. Sustaining the program would cost US $17,618 on average annually per district. Over 10 years, MOTECH could potentially save an estimated 59,906 lives at a total cost of US $32 million. The incremental cost per disability-adjusted life year averted ranged from US $174 in the first year to US $6.54 in the tenth year of implementation and US $20.94 (95% CI US $20.34-$21.55) over 10 years. Uncertainty analyses suggested that the incremental cost-effectiveness ratio was most sensitive to changes in health effects, followed by personnel time. Probabilistic sensitivity analyses suggested that MOTECH had a 100% probability of being cost-effective above a willingness-to-pay threshold of US $50. CONCLUSIONS This is the first study to estimate the value for money of the supply- and demand-side of an mHealth initiative. The adoption of MOTECH to improve MNCH service delivery and uptake represents good value for money in Ghana and should be considered for expansion. Integration with other mHealth solutions, including e-Tracker, may provide opportunities to continue or combine beneficial components of MOTECH to achieve a greater impact on health.

28 August 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EKEliza Mari Kwesi-Maliepaard
Eliza Mari Kwesi-Maliepaard
JOJudith A. Osea-Larbi
Judith A. Osea-Larbi
CNCelestine K. Nyamari
Celestine K. Nyamari
YAYakubu Alhassan
Yakubu Alhassan
ASAdelaide K. Sromani
Adelaide K. Sromani
YBYaw Bediako
Yaw Bediako
Background: The burden of cervical cancer is highest in Africa. Human papillomavirus (HPV) infection is the major cause of cervical cancer. There are over 200 different HPV genotypes, with 15 considered (potential) high-risk genotypes for developing cancer. Due to a lack of systematic screening programs in most African countries, there is limited data available on the most prevalent HPV genotypes in the population. This study aimed to assess the prevalence and distribution of HPV genotypes in cohorts in Ghana and Kenya. Methods: We analyzed HPV genotyping data from cervical samples submitted for diagnostic HPV genotype testing between July 2022 and March 2025. Our database contained results from samples obtained from outreach screening events in Accra, the capital of Ghana (n = 680), a research project in Ghana outside of Accra (n = 426), clinician-collected samples submitted through clinics in Ghana (n = 118), samples from participants in Ghana who independently sought HPV genotyping through community-based providers, pharmacies, clinics, or online testing services outside organized screening programmes (n = 181) and samples from an outreach screening event in Kenya (n = 46). All samples were from women 18 years old and above. Positivity for HPV genotypes (HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68) was determined by RT-PCR, using the AmpFire HPV High Risk Genotyping kit. Results: HPV positivity in the Ghana screening group was 34.9%, with multiple genotypes detected in 39.2% of the positive cases. The main HPV genotype in the Ghana screening group was HPV-39 (19.0%), which was especially prevalent in the younger age group (<30 years), followed by HPV-53 (15.2%) and HPV-68 (15.2%). HPV infection (Odds Ratio (OR) 3.09, Confidence Interval (CI) 1.92–4.97, p < 0.001) and infection with multiple genotypes (OR 3.45, CI 1.42–8.38, p = 0.006) was associated with younger age in the Ghana screening group. In the Ghana research group HPV-53 was the most common genotype (18.9%), followed by HPV-39 (18.0%). In the clinician-collected group HPV-16 (18.6%) was the most common genotype. In the self-collected samples from participants who independently sought HPV testing HPV-39 (17.9%) and HPV-51 (17.9%) were the most common genotypes. In the much smaller Kenya screening group HPV-51 (46.2%) was the most prevalent genotype. Conclusions: Our study shows HPV genotype distribution in different settings. This emphasizes the importance of systematic population-wide HPV screening to understand local HPV infections patterns.